US 11,938,127 B2
Methods and compositions relating to steroid hormone receptor-dependent proliferative disorders
Manohar Ratnam, Toledo, OH (US)
Assigned to Wayne State University, Detroit, MI (US)
Filed by Wayne State University, Detroit, MI (US)
Filed on Sep. 28, 2022, as Appl. No. 17/954,686.
Claims priority of provisional application 63/249,326, filed on Sep. 28, 2021.
Prior Publication US 2023/0102174 A1, Mar. 30, 2023
Int. Cl. A61K 31/4704 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4704 (2013.01) [A61P 35/00 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A pharmaceutical composition, comprising a compound having chemical structural formula I:

OG Complex Work Unit Chemistry
where R1 is selected from the group consisting of: an alkyl group, a heteroalkyl group, an aryl group, a heteroaryl group, an alkenyl group, a heteroalkenyl group, an alkynyl group, a heteroalkynyl group, a cycloalkyl group, a hetercycloalkyl group, an alkylcycloalkyl group, a heteroalkyl cycloalkyl group, an aralkyl group, a heteroaralkyl group, an alkoxy group, a polar group, an ester and a charged group; a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a pharmaceutically acceptable salt thereof;
where R4′ is H or an alkoxy group;
where both R5 and R3′ are OH, or where one or both OH groups is optionally modified as a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a deuterated form thereof; and/or a pharmaceutically acceptable salt thereof;
and a pharmaceutically acceptable carrier.